Top

Published in:

01-07-2020 | Systemic Lupus Erythematosus | Commentary

Within a large healthcare system, the incidence of positive COVID-19 results and mortality are lower in patients on chronic hydroxychloroquine therapy

Authors: Soma Sen, Ann Werner, Aditya Shekhar

Published in: Drugs & Therapy Perspectives | Issue 7/2020

Excerpt

In addition to causing significant mortality and adverse changes to the quality of life of billions globally, the COVID-19 pandemic has significantly burdened healthcare systems and will continue doing so unless more-effective means of management and treatment are identified [1]. Projections estimate that, without improved treatment methods, COVID-19 could cause 100,000–240,000 deaths in the USA [1]. In vitro and in vivo studies have identified the antimalarial medicine hydroxychloroquine as a potential pharmacological treatment option [2‐4]. Currently, hydroxychloroquine is a well-established medication prescribed to treat systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) [4]. …

Shear MD, Crowley M, Glanz J. Coronavirus may kill 100,000 to 240,000 in U.S. despite actions, officials say. New York: New York Times; 31 Mar 2020. https://www.nytimes.com/2020/03/31/us/politics/coronavirus-death-toll-united-states.html. Accessed 1 Apr 2020.

World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 [media briefing 11 Mar 2020]. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-atthe-media-briefing-on-COVID-19. Accessed 1 Apr 2020.

Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. https://doi.org/10.1093/cid/ciaa237(Epub 2020 Mar 9).CrossRefPubMedPubMedCentral

Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. https://doi.org/10.1016/j.ijantimicag.2020.105949(Epub 20 Mar 2020).CrossRefPubMedPubMedCentral

Colson P, Rolain JM, Lagier JC, et al. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 [editorial]. Int J Antimicrob Agents. 2020;55(4):105932.CrossRefPubMedPubMedCentral

Title: Within a large healthcare system, the incidence of positive COVID-19 results and mortality are lower in patients on chronic hydroxychloroquine therapy
Authors: Soma Sen
Ann Werner
Aditya Shekhar
Publication date: 01-07-2020
Publisher: Springer International Publishing
Keywords: Systemic Lupus Erythematosus
COVID-19
Rheumatoid Arthritis
Hydroxychloroquine
Published in: Drugs & Therapy Perspectives / Issue 7/2020
Print ISSN: 1172-0360
Electronic ISSN: 1179-1977
DOI: https://doi.org/10.1007/s40267-020-00741-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Within a large healthcare system, the incidence of positive COVID-19 results and mortality are lower in patients on chronic hydroxychloroquine therapy

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 7/2020

Effectiveness of duloxetine for remnant pain relief in patients with rheumatoid arthritis despite remission

Be alert for macrophage activation syndrome in seriously sick children with underlying pro-inflammatory disorders

Is Pakistan on track to have COVID-19 transmission and mortality rates similar to those of Italy, Iran or the USA?

Amid COVID-19 drug shortages: proposed plan for reprocessing and reusing salbutamol pressurized metered dose inhalers (pMDIs) for shared use

Adverse drug reactions and interactions: first reports and special situations

Correction to: First reports of adverse drug reactions